<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="*Correspondence: Margarita K. Lay margarita.lay@uantof.cl This article was submitted to" exact="Viral" post="Immunology, a section of the journal Frontiers in Immunology"/>
 <result pre="are the cause of more than 95% of epidemic non-bacterial" exact="gastroenteritis" post="worldwide, with some lethal cases. These viral agents affect"/>
 <result pre="of epidemic non-bacterial gastroenteritis worldwide, with some lethal cases. These" exact="viral" post="agents affect people of all ages. However, young children"/>
 <result pre="structural and non-structural proteins and their possible role within the" exact="viral" post="replicative cycle and the pathogenesis of the virus. It"/>
 <result pre="relevance for diagnostics and vaccine development so as to prevent" exact="infections" post="caused by these fastidious viruses. human norovirus proteins replication"/>
 <result pre="Introduction Human noroviruses (HuNoV) are the main cause of non-bacterial" exact="gastroenteritis" post="worldwide, producing high morbidity and mortality rates (1, 2)."/>
 <result pre="United States, it is estimated that the burden of the" exact="disease" post="caused by HuNoV infection produces 570–800 deaths, 56,000–71,000 hospitalizations,"/>
 <result pre="estimated that the burden of the disease caused by HuNoV" exact="infection" post="produces 570–800 deaths, 56,000–71,000 hospitalizations, 400,000 visits to the"/>
 <result pre="1.7–1.9 million ambulatory visits to health centers, and 19–21 million" exact="total" post="diseases per year (4). Although HuNoV can infect people"/>
 <result pre="visiting developing countries (10, 11). HuNoV produces rapid and self-limited" exact="acute" post="gastroenteritis characterized by the development of symptoms such as"/>
 <result pre="developing countries (10, 11). HuNoV produces rapid and self-limited acute" exact="gastroenteritis" post="characterized by the development of symptoms such as vomiting,"/>
 <result pre="characterized by the development of symptoms such as vomiting, watery" exact="diarrhea" post="with or without nausea, and abdominal cramps (12). HuNoV"/>
 <result pre="(GI–GX) (13). Only GI, GII, and GIV infect and cause" exact="acute" post="gastroenteritis in humans. These genogroups are classified according to"/>
 <result pre="(13). Only GI, GII, and GIV infect and cause acute" exact="gastroenteritis" post="in humans. These genogroups are classified according to the"/>
 <result pre="worldwide is GII.4 (2, 15), cases caused by other highly" exact="infectious" post="genotypes, such as GII.17, have been detected (17, 18)."/>
 <result pre="no availability of small animal models that emulate the human" exact="disease" post="so as to perform pre-clinical studies makes even more"/>
 <result pre="genogroups in zebrafish larvae has also been developed (21). Nevertheless," exact="limited" post="information regarding the viral replication cycle and the immune"/>
 <result pre="has also been developed (21). Nevertheless, limited information regarding the" exact="viral" post="replication cycle and the immune response against HuNoV is"/>
 <result pre="Knowledge in these areas will allow a better understanding of" exact="viral" post="pathogenesis and the design of efficient strategies to develop"/>
 <result pre="HuNoV structural and non-structural proteins and their role in the" exact="viral" post="replicative cycle and pathogenesis, as well as insights of"/>
 <result pre="7.5–7.7 kb covalently bound to a non-structural (NS) protein, called" exact="viral" post="protein genome-linked (VPg), at the 5′ end and polyadenylated"/>
 <result pre="(26–28). Likewise, ORF2 encodes the major structural protein of the" exact="viral" post="capsid VP1, and ORF3 encodes the minor structural protein"/>
 <result pre="are displayed in Figure 1, and the nomenclature of its" exact="viral" post="proteins is shown in Table 1. Figure 1 Molecular"/>
 <result pre="protein VP2 (1–8 proteins per virion) is shown within the" exact="viral" post="capsid. The non-structural VPg protein, covalently bound to the"/>
 <result pre="poly-adenine tail at the 3′ ends are also displayed. (B)" exact="General" post="scheme of the HuNoV genome organization. ORF1 encodes the"/>
 <result pre="• p48 • N-terminal ° Modulate the activity of the" exact="viral" post="polymerase (RdRp). ° Alter multiple immune systems. ° Function"/>
 <result pre="initiation factors such as eIF3. ° Direct the synthesis of" exact="viral" post="proteins. (33) NS 6 • Protease • Protect like"/>
 <result pre="3CLpro • ProPol* • NS6pro ° Responsible for processing the" exact="viral" post="polyprotein. (33) NS7 • Polymerase • Pol • 3Dpol*"/>
 <result pre="3Dpol* • RdRp • ProPol** • NS7pol ° Translation of" exact="viral" post="RNA. (33, 37) VP 1 • Viral protein 1"/>
 <result pre="° Translation of viral RNA. (33, 37) VP 1 •" exact="Viral" post="protein 1 • The major protein of the capsid"/>
 <result pre="Viral protein 1 • The major protein of the capsid" exact="viral" post="° Structural protein. ° Binding of the virus to"/>
 <result pre="to HBGA. ° Immune escape. (22, 38) VP 2 •" exact="Viral" post="protein 2 • The minor protein of the capsid"/>
 <result pre="Viral protein 2 • The minor protein of the capsid" exact="viral" post="° Translation of viral RNA. ° Structural protein. °"/>
 <result pre="The minor protein of the capsid viral ° Translation of" exact="viral" post="RNA. ° Structural protein. ° Stability of the viral"/>
 <result pre="of viral RNA. ° Structural protein. ° Stability of the" exact="viral" post="capsid. (28) *These nomenclatures are made based on the"/>
 <result pre="group antigens (HBGAs) using the same patterns as the native" exact="viral" post="capsid, playing a role in the virus–cell receptor interaction"/>
 <result pre="Moreover, these sites are exposed on the surface of the" exact="viral" post="capsid, suggesting that the P2 region could exhibit specific"/>
 <result pre="subdomain being the region with the highest exposure of the" exact="viral" post="particle, which allows its interaction with the HBGAs and"/>
 <result pre="escape of herd immunity is promoted when these changes in" exact="viral" post="antigenicity are generated, resulting in new HuNoV outbreaks in"/>
 <result pre="is essential for the classification of these viruses. VP2 The" exact="viral" post="protein 2 (VP2) is the minor structural protein of"/>
 <result pre="weight of 29 kDa and which is located inside the" exact="viral" post="capsid. VP2 is one of the less-studied HuNoV proteins."/>
 <result pre="and coordinates the formation of VLPs (28, 55). Indeed the" exact="absence of" post="VP2 decreases the stability and the homogeneity of the"/>
 <result pre="that VP1 was expressed, located throughout the cytosol, in the" exact="absence of" post="VP2. In contrast, VP2 was expressed in the absence"/>
 <result pre="absence of VP2. In contrast, VP2 was expressed in the" exact="absence of" post="VP1 and was observed to be located in the"/>
 <result pre="and Functions of Non-structural Proteins of HuNoV p48 or N-Terminal" exact="Protein" post="The p48 protein, also denoted as N-terminal (NS1-2), is"/>
 <result pre="N-terminus of the polyprotein. When it is cleaved by the" exact="viral" post="protease, it results in a mature NS1-2 protein. In"/>
 <result pre="of the p48 protein of the different HuNoVs within the" exact="viral" post="replicative cycle and its role in HuNoV pathogenesis in"/>
 <result pre="of p48 as a fusion protein in COS-7 cells, an" exact="African" post="green monkey kidney fibroblast-like cell line, revealed that this"/>
 <result pre="the interaction of p48 with VAP-A. The p48 protein is" exact="localized" post="in the vesicle membranes of the ER, the trans-Golgi"/>
 <result pre="p48 with VAP-A. The p48 protein is localized in the" exact="vesicle" post="membranes of the ER, the trans-Golgi network, and the"/>
 <result pre="HuNoV replicative cycle by participating in the development of the" exact="viral" post="replication complex and by hampering the normal function of"/>
 <result pre="as, the activation of the immune response induced by the" exact="viral infection." post="NTPase The NTPase protein, also denoted as NS3, is"/>
 <result pre="NTPase protein, also denoted as NS3, is cleaved by the" exact="viral" post="protease at the 331 and 696 aa of the"/>
 <result pre="possesses fundamental enzymatic activities that play a significant role in" exact="viral" post="replication, such as (a) NTP-dependent helicase activity for unrolling"/>
 <result pre="protein was determined through a confocal immunofluorescence analysis in human" exact="melanoma" post="A7 cells, determining that this protein can form vesicular"/>
 <result pre="called p20 (NS4), when excised from the polyprotein by the" exact="viral" post="protease, results in a mature NS protein of 20–22"/>
 <result pre="which is higher than the evolutionary rate determined for the" exact="complete" post="genome, being one of the most variable genomic regions"/>
 <result pre="tubular membranes play a critical role in the development of" exact="viral" post="replicative complexes in RNA(+) viruses. Indeed in an in"/>
 <result pre="together with the p48 and NTPase, the formation of the" exact="viral" post="replication complex (64). Remarkably, HuNoV p22 is very similar"/>
 <result pre="by altering the interferon and other cytokine signaling pathways after" exact="viral infection" post="(35, 36). Thus, the HuNoV p22 protein could play"/>
 <result pre="altering the interferon and other cytokine signaling pathways after viral" exact="infection" post="(35, 36). Thus, the HuNoV p22 protein could play"/>
 <result pre="of the immune response. Besides that, it promotes the replicative" exact="viral" post="complex assembly. VPg The HuNoV VPg (NS5) genome-linked protein"/>
 <result pre="that is covalently linked to the 5′ end of the" exact="viral" post="RNA genome. VPg is cleaved by the HuNoV protease"/>
 <result pre="of Mn+2, resulting in the binding of VPg to the" exact="viral" post="RNA, thus facilitating the HuNoV genome replication by acting"/>
 <result pre="the HuNoV genome replication by acting as a primer in" exact="viral" post="RNA synthesis, which is mediated by the RdRp (66)."/>
 <result pre="was described that VPg can participate in the initiation of" exact="viral" post="RNA translation by binding to the cell translation initiation"/>
 <result pre="and the &quot;core stress granule component�? (G3BP1) is important for" exact="viral" post="protein synthesis and replication since this complex binds to"/>
 <result pre="components of the host play an important role in the" exact="viral" post="replicative cycle and the pathogenesis of HuNoV. Protease Protease"/>
 <result pre="pathogenesis of HuNoV. Protease Protease plays a fundamental role in" exact="viral" post="activities by cleaving the proteins involved in genome replication,"/>
 <result pre="which processes the NS proteins by cleaving them from the" exact="viral" post="polyprotein (61). It has an approximate molecular weight of"/>
 <result pre="9.0, increasing its activity at a higher pH than the" exact="viral" post="protease by itself. Moreover, ProPol has higher activity (64%)"/>
 <result pre="a protein cleavage efficiency equal to or greater than the" exact="viral" post="protease itself at all the polyprotein cleavage sites (77)."/>
 <result pre="sites (77). Therefore, the ProPol precursor can function as the" exact="dominant form" post="of the HuNoV protease. Polymerase The HuNoV polymerase protein,"/>
 <result pre="a RdRp whose main function is the replication of the" exact="viral" post="genome. This protein is cleaved by the HuNoV protease"/>
 <result pre="suggesting that ProPol is a bifunctional complex that acts during" exact="viral" post="replication (37, 61). The three-dimensional structure of the NV"/>
 <result pre="of other viruses, varying only in the sense that this" exact="viral" post="Pol has a carboxyl terminal in the slit of"/>
 <result pre="active site that could be involved in the synthesis of" exact="viral" post="RNA (78). Phylogenetically, the Pol region has been used"/>
 <result pre="as the primordial step that precedes the entry of a" exact="viral" post="particle into the cell (80). HBGAs are polymorphic glucans"/>
 <result pre="on the cell surface of red blood cells or the" exact="epithelial" post="cells of some tissues (81). In HuNoV, the HBGA"/>
 <result pre="studies that indicate that several individuals are resistant to HuNoV" exact="infection" post="(84). The HBGA generation is mediated by the enzyme"/>
 <result pre="functional gene are called non-secretors and are resistant to HuNoV" exact="infection" post="(81). HBGA, as a pivotal factor in the susceptibility"/>
 <result pre="as a pivotal factor in the susceptibility of individuals to" exact="virus infection," post="has also been reported in other enteric viruses such"/>
 <result pre="85, 86). The first link between HBGA variability and HuNoV" exact="infection" post="was suggested from clinical studies of volunteers infected with"/>
 <result pre="receptor(s), internalization of the virus and subsequent disassembly of the" exact="viral" post="capsid occur, releasing the RNA into the cell cytoplasm."/>
 <result pre="processes take place has not yet been described. Once the" exact="viral" post="genome is released, the VPg protein, which is covalently"/>
 <result pre="which is covalently linked at the 5′ end of the" exact="viral" post="genome, interacts with the cellular translation initiation factors, such"/>
 <result pre="individual proteins have specific functions in the replicative and the" exact="infective" post="cycles. The replication process is carried out by the"/>
 <result pre="will enhance the Pol activity (57). Then, synthesis of the" exact="viral" post="genome and the sub-genomes with the VPg protein, attached"/>
 <result pre="mobilized by the NTPase protein chaperone activity (62, 89). A" exact="viral" post="polyprotein will be produced from the translation of the"/>
 <result pre="viral polyprotein will be produced from the translation of the" exact="viral" post="genome, and VP1 and VP2 proteins will be generated"/>
 <result pre="binding of major and minor ribosomal subunits, producing genome translation" exact="viral" post="thus generating a non-structural polyprotein, the VP1 protein, and"/>
 <result pre="cleavage activity. (F) The Pol protein exerts its function in" exact="viral" post="replication, whose activity is greatly enhanced by the action"/>
 <result pre="system are raised against RNA viruses such as HuNoV, the" exact="type I" post="and III interferon (IFN) systems controlling viral replication (94,"/>
 <result pre="HuNoV, the type I and III interferon (IFN) systems controlling" exact="viral" post="replication (94, 95). Particularly, RNA viruses are mainly detected"/>
 <result pre="and the RIG-I like receptor (RLR) family members. TLR3 is" exact="localized" post="in the intracellular compartment in macrophages, B lymphocytes, and"/>
 <result pre="be one of the host antiviral mechanisms in controlling HuNoV" exact="infection" post="(96). Furthermore, the following evidences suggest that the type"/>
 <result pre="HuNoV infection (96). Furthermore, the following evidences suggest that the" exact="type I" post="and III IFN systems can play an important role"/>
 <result pre="(97); (b) the replication of MNV-1 is sensitive to the" exact="type I" post="and III IFN systems both in vivo and in"/>
 <result pre="(20). Interestingly, bile acids have previously been reported to down-regulate" exact="type I" post="and III IFN pathways and enhance the growth of"/>
 <result pre="the downregulation of these IFN pathways allows and enhances HuNoV" exact="infection" post="in human cells, although it has been challenging to"/>
 <result pre="transfecting NV RNA in Huh-7 cells does not induce strong" exact="type I" post="IFN responses (102). Using the NV RNA transfection method"/>
 <result pre="it was likewise recently reported that HuNoV does not induce" exact="type I" post="or type III IFN pathway in the human cell"/>
 <result pre="recently reported that HuNoV does not induce type I or" exact="type III" post="IFN pathway in the human cell line 293FT (103)."/>
 <result pre="HuNoV replication was sensitive to the three types of IFNs:" exact="type I" post="IFN (IFNα), type II IFN (IFNγ), and type III"/>
 <result pre="to the three types of IFNs: type I IFN (IFNα)," exact="type II" post="IFN (IFNγ), and type III IFN (IFNλ1 and 3)."/>
 <result pre="IFNs: type I IFN (IFNα), type II IFN (IFNγ), and" exact="type III" post="IFN (IFNλ1 and 3). Furthermore, by expressing different interferon-stimulated"/>
 <result pre="by expressing different interferon-stimulated genes (ISGs) into the human Huh7" exact="hepatocellular carcinoma" post="cells expressing the NV replicon (HG23), RTP4, and HPSE"/>
 <result pre="expressing different interferon-stimulated genes (ISGs) into the human Huh7 hepatocellular" exact="carcinoma" post="cells expressing the NV replicon (HG23), RTP4, and HPSE"/>
 <result pre="IRF-1 was predominantly induced in HGC3 by treating them with" exact="type II" post="IFN. Interestingly, these investigators demonstrated that there is a"/>
 <result pre="antibody levels against HuNoV are correlated with protection against future" exact="infections" post="by these viruses. Several studies in the literature indicate"/>
 <result pre="antibodies against NV in adults correlate with protection against future" exact="infections" post="by this virus (GI.1 genotype) (105, 106). Likewise, the"/>
 <result pre="(105, 106). Likewise, the results of other studies, conducted in" exact="adult" post="volunteers, revealed that the presence of high serum or"/>
 <result pre="serum or fecal titers of specific antibodies for NV before" exact="infection" post="decreased the probability of becoming infected by this virus,"/>
 <result pre="50% of the volunteers infected with this HuNoV had repeated" exact="infections" post="after 3 years compared to the other 50% who"/>
 <result pre="3 years compared to the other 50% who remained without" exact="infection" post="during and after repeated challenges (111). The problem of"/>
 <result pre="could not be demonstrated whether these volunteers were exempt from" exact="disease" post="due to acquired immunity or their genetic resistance traits"/>
 <result pre="demonstrated whether these volunteers were exempt from disease due to" exact="acquired" post="immunity or their genetic resistance traits to the virus."/>
 <result pre="some volunteers who became ill after a NV challenge showed" exact="partial" post="immunity against the disease in a re-exposure after 6–14"/>
 <result pre="ill after a NV challenge showed partial immunity against the" exact="disease" post="in a re-exposure after 6–14 weeks. However, this partial"/>
 <result pre="the disease in a re-exposure after 6–14 weeks. However, this" exact="partial" post="immune protection was completely lost after 2–3 years (111)."/>
 <result pre="herd immunity in the population that protects against GII.4 HuNoV" exact="infections" post="(46, 119, 120). However, it is important to keep"/>
 <result pre="in mind that individuals can become susceptible again to the" exact="disease" post="if a new strain of GII.4 appears. Furthermore, the"/>
 <result pre="the correlation between neutralizing antibody titers and protection against future" exact="infections" post="is also unclear. It has been shown that the"/>
 <result pre="of blocking the binding of GII.4 VLPs to HBGA H" exact="type 3" post="in the serum of uninfected children during a waterborne"/>
 <result pre="the serum of uninfected children during a waterborne outbreak of" exact="acute" post="gastroenteritis, suggesting that strong blocking activity correlated with protection"/>
 <result pre="that a NV (GI.1) failed to confer immunity to subsequent" exact="disease" post="caused by the Hawaii virus (GII.1) and the opposite."/>
 <result pre="cross-reactivity and cross-blockade activity, using serum samples from HuNoV-infected patients," exact="limited" post="cross-reactivity was found but no cross-blockade activity between GII.4"/>
 <result pre="the GII.17 genotype (125). In summary, humoral protection after HuNoV" exact="infection" post="has very complex patterns of heterotypic immune responses. To"/>
 <result pre="the serum of HuNoV-infected individuals guarantees long-term protection against future" exact="infections" post="by these viruses, most likely due to the rapid"/>
 <result pre="is available for studying the adaptive immune to HuNoV. Therefore," exact="limited" post="information is available regarding the cellular immune response against"/>
 <result pre="strain (GII.2-1976) or in fecal samples from travelers with HuNoV" exact="gastroenteritis" post="(128). Particularly, peripheral blood mononuclear cells (PBMCs) from healthy"/>
 <result pre="in fecal samples from travelers with HuNoV gastroenteritis (128). Particularly," exact="peripheral" post="blood mononuclear cells (PBMCs) from healthy volunteers challenged with"/>
 <result pre="the SMV challenge and found that CD4+ cells were the" exact="primary" post="source of IFN-γ secretion in PBMCs stimulated in vitro"/>
 <result pre="of immunodominant epitopes over time, suggests an evolution of the" exact="viral" post="capsid, allowing HuNoVs not only to escape from the"/>
 <result pre="of research based on NS proteins of HuNoV has been" exact="limited" post="to in vitro cultures that have provided information about"/>
 <result pre="In contrast, protein VP2 acts as a stabilizer of the" exact="viral" post="capsid and, during viral replication, it enhances the expression"/>
 <result pre="acts as a stabilizer of the viral capsid and, during" exact="viral" post="replication, it enhances the expression of VP1 protein and"/>
 <result pre="only with the Lewis and/or H antigens. Although the HuNoV" exact="viral" post="replicative cycle has not been fully clarified due to"/>
 <result pre="NS proteins are released from the generated polyprotein by the" exact="viral" post="protease, which is self-cleaved first; (3) p48 and p22"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="and molecular trends of &quot;Norwalk-like viruses�? associated with outbreaks of" exact="gastroenteritis" post="in the United States. J Infect Dis. (2002) 186:1–7."/>
 <result pre="of norovirus gastroenteritis. PLoS ONE. (2016) 11:e0151219. 10.1371/journal.pone.015121927115736 4.HallAJLopmanBAPayneDCPatelMMGastanaduyPAVinjeJet al.Norovirus" exact="disease" post="in the United States. Emerg Infect Dis. (2013) 19:1198–205."/>
 <result pre="10.1186/1471-2458-3-1312659651 7.FankhauserRLNoelJSMonroeSSAndoTGlassRI. Molecular epidemiology of &quot;Norwalk-like viruses�? in outbreaks of" exact="gastroenteritis" post="in the United States. J Infect Dis. (1998) 178:1571–8."/>
 <result pre="of morbidity. Clin Infect Dis. (2009) 49:1061–8. 10.1086/60555719705974 9.WesthoffTHVergoulidouMLoddenkemperCSchwartzSHofmannJSchneiderTet al.." exact="Chronic" post="norovirus infection in renal transplant recipients. Nephrol Dial Transplant."/>
 <result pre="morbidity. Clin Infect Dis. (2009) 49:1061–8. 10.1086/60555719705974 9.WesthoffTHVergoulidouMLoddenkemperCSchwartzSHofmannJSchneiderTet al.. Chronic" exact="norovirus infection" post="in renal transplant recipients. Nephrol Dial Transplant. (2009) 24:1051–3."/>
 <result pre="Clin Infect Dis. (2009) 49:1061–8. 10.1086/60555719705974 9.WesthoffTHVergoulidouMLoddenkemperCSchwartzSHofmannJSchneiderTet al.. Chronic norovirus" exact="infection" post="in renal transplant recipients. Nephrol Dial Transplant. (2009) 24:1051–3."/>
 <result pre="Dial Transplant. (2009) 24:1051–3. 10.1093/ndt/gfn69319073655 10.AjamiNKooHDarkohCAtmarRLOkhuysenPCJiangZDet al.. Characterization of norovirus-associated" exact="traveler's diarrhea." post="Clin Infect Dis. (2010) 51:123–30. 10.1086/65353020540620 11.KooHLAjamiNJJiangZDNeillFHAtmarRLEricssonCDet al.. Noroviruses"/>
 <result pre="(2010) 51:123–30. 10.1086/65353020540620 11.KooHLAjamiNJJiangZDNeillFHAtmarRLEricssonCDet al.. Noroviruses as a cause of" exact="diarrhea" post="in travelers to Guatemala, India, and Mexico. J Clin"/>
 <result pre="and Mexico. J Clin Microbiol. (2010) 48:1673–6. 10.1128/JCM.02072-0920305012 12.GrahamDYJiangXTanakaTOpekunARMadoreHPEstesMK. Norwalk" exact="virus infection" post="of volunteers: new insights based on improved assays. J"/>
 <result pre="Mexico. J Clin Microbiol. (2010) 48:1673–6. 10.1128/JCM.02072-0920305012 12.GrahamDYJiangXTanakaTOpekunARMadoreHPEstesMK. Norwalk virus" exact="infection" post="of volunteers: new insights based on improved assays. J"/>
 <result pre="and genetic variability of small round-structured viruses in outbreaks of" exact="gastroenteritis" post="in The Netherlands. J Infect Dis. (1997) 176:1374–8. 10.1086/5173259359742"/>
 <result pre="in The Netherlands. J Infect Dis. (1997) 176:1374–8. 10.1086/5173259359742 16.TamminenKMalmMVesikariTBlazevicV." exact="Immunological" post="cross-reactivity of an ancestral and the most recent pandemic"/>
 <result pre="SNARE regulator VAP-A and prevents cell surface expression of vesicular" exact="stomatitis" post="virus G protein. J Virol. (2003) 77:11790–7. 10.1128/JVI.77.21.11790-11797.200314557663 31.HuangPFarkasTZhongWTanMThorntonSMorrowALet"/>
 <result pre="implications for epochal evolution. J Virol. (2011) 85:8635–45. 10.1128/JVI.00848-1121715503 50.DonaldsonEFLindesmithLCLobueADBaricRS." exact="Viral" post="shape-shifting: norovirus evasion of the human immune system. Nat"/>
 <result pre="al.. Structural and functional changes of the duodenum in human" exact="norovirus infection." post="Gut. (2009) 58:1070–7. 10.1136/gut.2008.16015019036950 52.BullRATanakaMMWhitePA. Norovirus recombination. J Gen"/>
 <result pre="55.LinYFenglingLLianzhuWYuxiuZYanhuaJ. Function of VP2 protein in the stability of the" exact="secondary" post="structure of virus-like particles of genogroup II norovirus at"/>
 <result pre="proteolytic processing of the MD145 norovirus ORF1 non-structural polyprotein yields" exact="stable" post="precursors and products similar to those detected in calicivirus-infected"/>
 <result pre="Noroviruses subvert the core stress granule component G3BP1 to promote" exact="viral" post="VPg-dependent translation. Elife. (2019) 8:e46681. 10.7554/eLife.4668131403400 69.McSweeneyADaviesCWardVK. Cell cycle"/>
 <result pre="the norovirus polyprotein precursor by two active forms of the" exact="viral" post="protease. J Gen Virol. (2007) 88:2013–8. 10.1099/vir.0.82797-017554035 77.MayJKorbaBMedvedevAViswanathanP. Enzyme"/>
 <result pre="86:284–92. 10.1128/JVI.05909-1122031945 84.LindesmithLMoeCMarionneauSRuvoenNJiangXLindbladLet al.. Human susceptibility and resistance to Norwalk" exact="virus infection." post="Nat Med. (2003) 9:548–53. 10.1038/nm86012692541 85.HemmingMRäsänenSHuhtiLPaloniemiMSalminenMVesikariT. Major reduction of"/>
 <result pre="9:548–53. 10.1038/nm86012692541 85.HemmingMRäsänenSHuhtiLPaloniemiMSalminenMVesikariT. Major reduction of rotavirus, but not norovirus," exact="gastroenteritis" post="in children seen in hospital after the introduction of"/>
 <result pre="10.1007/s00431-013-1945-323361964 86.RamaniSGiriS. Influence of histo blood group antigen expression on" exact="susceptibility to" post="enteric viruses and vaccines. Curr Opin Infect Dis. (2019)"/>
 <result pre="Norwalk virus binds to histo-blood group antigens present on gastroduodenal" exact="epithelial" post="cells of secretor individuals. Gastroenterology. (2002) 122:1967–77. 10.1053/gast.2002.3366112055602 88.HuangPFarkasTMarionneauSZhongWRuvoën-ClouetNMorrowALet"/>
 <result pre="Infect Dis. (2003) 188:19–31. 10.1086/37574212825167 89.ShiratoHOgawaSItoHSatoTKameyamaANarimatsuHet al.. Noroviruses distinguish between" exact="type 1" post="and type 2 histo-blood group antigens for binding. J"/>
 <result pre="188:19–31. 10.1086/37574212825167 89.ShiratoHOgawaSItoHSatoTKameyamaANarimatsuHet al.. Noroviruses distinguish between type 1 and" exact="type 2" post="histo-blood group antigens for binding. J Virol. (2008) 82:10756–67."/>
 <result pre="terminal sequence in vitro. Virology. (2017) 503:37–45. 10.1016/j.virol.2017.01.00328110248 91.HutsonAMAtmarRLGrahamDYEstesMK. Norwalk" exact="virus infection" post="and disease is associated with ABO histo-blood group type."/>
 <result pre="sequence in vitro. Virology. (2017) 503:37–45. 10.1016/j.virol.2017.01.00328110248 91.HutsonAMAtmarRLGrahamDYEstesMK. Norwalk virus" exact="infection" post="and disease is associated with ABO histo-blood group type."/>
 <result pre="vitro. Virology. (2017) 503:37–45. 10.1016/j.virol.2017.01.00328110248 91.HutsonAMAtmarRLGrahamDYEstesMK. Norwalk virus infection and" exact="disease" post="is associated with ABO histo-blood group type. J Infect"/>
 <result pre="(2008) 225:190–211. 10.1111/j.1600-065X.2008.00680.x18837783 94.LeeSBaldridgeMT. Interferon-lambda: a potent regulator of intestinal" exact="viral" post="infections. Front Immunol. (2017) 8:749. 10.3389/fimmu.2017.0074928713375 95.JensenSThomsenAR. Sensing of"/>
 <result pre="recognizing RNA virus invasion. J Virol. (2012) 86:2900–10. 10.1128/JVI.05738-1122258243 96.ChangKOSosnovtsevSVBelliotGKingADGreenKY." exact="Stable" post="expression of a Norwalk virus RNA replicon in a"/>
 <result pre="10.1016/j.virol.2006.06.00616843517 97.SouzaMCheethamSMAzevedoMSCostantiniVSaifLJ. Cytokine and antibody responses in gnotobiotic pigs after" exact="infection" post="with human norovirus genogroup II.4 (HS66 strain). J Virol."/>
 <result pre="Biol. (2004) 2:e432. 10.1371/journal.pbio.002043215562321 100.GuixSAsanakaMKatayamaKCrawfordSENeillFHAtmarRLet al.. Norwalk virus RNA is" exact="infectious" post="in mammalian cells. J Virol. (2007) 81:12238–48. 10.1128/JVI.01489-0717855551 101.ChangKOSosnovtsevSVBelliotGKimYSaifLJGreenKY."/>
 <result pre="Antiviral Res. (2018) 155:48–59. 10.1016/j.antiviral.2018.05.00429753657 105.JohnsonPCMathewsonJJDuPontHLGreenbergHB. Multiple-challenge study of host" exact="susceptibility to" post="Norwalk gastroenteritis in US adults. J Infect Dis. (1990)"/>
 <result pre="155:48–59. 10.1016/j.antiviral.2018.05.00429753657 105.JohnsonPCMathewsonJJDuPontHLGreenbergHB. Multiple-challenge study of host susceptibility to Norwalk" exact="gastroenteritis" post="in US adults. J Infect Dis. (1990) 161:18–21. 10.1093/infdis/161.1.182153184"/>
 <result pre="in US adults. J Infect Dis. (1990) 161:18–21. 10.1093/infdis/161.1.182153184 106.OkhuysenPCJiangXYeLJohnsonPCEstesMK." exact="Viral" post="shedding and fecal IgA response after Norwalk virus infection."/>
 <result pre="10.1093/infdis/161.1.182153184 106.OkhuysenPCJiangXYeLJohnsonPCEstesMK. Viral shedding and fecal IgA response after Norwalk" exact="virus infection." post="J Infect Dis. (1995) 171:566–9. 10.1093/infdis/171.3.5667876602 107.GrayJCunliffeCBallJGrahamDYDesselbergerUEstesMK. Detection of"/>
 <result pre="enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in" exact="adult" post="volunteers challenged with Norwalk virus. J Clin Microbiol. (1994)"/>
 <result pre="150:531–4. 10.1093/infdis/150.4.5316092484 109.LewJFValdesusoJVesikariTKapikianAZJiangXEstesMKet al.Detection of Norwalk virus or Norwalk-like virus" exact="infections" post="in Finnish infants and young children. J Infect Dis."/>
 <result pre="109.LewJFValdesusoJVesikariTKapikianAZJiangXEstesMKet al.Detection of Norwalk virus or Norwalk-like virus infections in" exact="Finnish" post="infants and young children. J Infect Dis. (1994) 169:1364–7."/>
 <result pre="responsible for vaccination against and clearance of mucosal and lymphatic" exact="norovirus infection." post="PLoS Pathogens. (2008) 4:236. 10.1371/journal.ppat.100023619079577 111.ParrinoTASchreiberDSTrierJSKapikianAZBlacklowNR. Clinical immunity in"/>
 <result pre="infection. PLoS Pathogens. (2008) 4:236. 10.1371/journal.ppat.100023619079577 111.ParrinoTASchreiberDSTrierJSKapikianAZBlacklowNR. Clinical immunity in" exact="acute" post="gastroenteritis caused by Norwalk agent. N Engl J Med."/>
 <result pre="PLoS Pathogens. (2008) 4:236. 10.1371/journal.ppat.100023619079577 111.ParrinoTASchreiberDSTrierJSKapikianAZBlacklowNR. Clinical immunity in acute" exact="gastroenteritis" post="caused by Norwalk agent. N Engl J Med. (1977)"/>
 <result pre="(1977) 297:86–9. 10.1056/NEJM197707142970204405590 112.WyattRGDolinRBlacklowNRDuPontHLBuschoRFThornhillTSet al.. Comparison of three agents of" exact="acute" post="infectious non-bacterial gastroenteritis by cross-challenge in volunteers. J Infect"/>
 <result pre="297:86–9. 10.1056/NEJM197707142970204405590 112.WyattRGDolinRBlacklowNRDuPontHLBuschoRFThornhillTSet al.. Comparison of three agents of acute" exact="infectious" post="non-bacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis."/>
 <result pre="112.WyattRGDolinRBlacklowNRDuPontHLBuschoRFThornhillTSet al.. Comparison of three agents of acute infectious non-bacterial" exact="gastroenteritis" post="by cross-challenge in volunteers. J Infect Dis. (1974) 129:709–14."/>
 <result pre="cross-challenge in volunteers. J Infect Dis. (1974) 129:709–14. 10.1093/infdis/129.6.7094209723 113.AgusSGDolinRWyattRGTousimisAJNorthrupRSAcute" exact="infectious" post="non-bacterial gastroenteritis: intestinal histopathology. Histologic and enzymatic alterations during"/>
 <result pre="4 genotype dominate as a cause of nosocomial outbreaks of" exact="viral" post="gastroenteritis in Sweden 1997–2005: Arrival of new variants is"/>
 <result pre="genotype dominate as a cause of nosocomial outbreaks of viral" exact="gastroenteritis" post="in Sweden 1997–2005: Arrival of new variants is associated"/>
 <result pre="J Clin Virol. (2008) 42:135–40. 10.1016/j.jcv.2008.02.01418420454 118.TuET-VBullRAGreeningGEHewittJLyonMJMarshallJAet al.. Epidemics of" exact="gastroenteritis" post="during 2006 were associated with the spread of norovirus"/>
 <result pre="122.LindesmithLCDonaldsonELeonJMoeCLFrelingerJAJohnstonREet al.. Heterotypic humoral and cellular immune responses following Norwalk" exact="virus infection." post="J Virol. (2010) 84:1800–15. 10.1128/JVI.02179-0920007270 123.RockxBHVennemaHHoebeCJDuizerEKoopmansMP. Association of histo-blood"/>
 <result pre="(2010) 84:1800–15. 10.1128/JVI.02179-0920007270 123.RockxBHVennemaHHoebeCJDuizerEKoopmansMP. Association of histo-blood group antigens and" exact="susceptibility to" post="norovirus infections. J Infect Dis. (2005) 191:749–54. 10.1086/42777915688291 124.NurminenKBlazevicVHuhtiLRasanenSKohoTHytonenVPet"/>
 <result pre="191:749–54. 10.1086/42777915688291 124.NurminenKBlazevicVHuhtiLRasanenSKohoTHytonenVPet al.. Prevalence of norovirus GII-4 antibodies in" exact="Finnish" post="children. J Med Virol. (2011) 83:525–31. 10.1002/jmv.2199021264875 125.DaiY-CXiaMHuangQTanMQinLZhuangY-Let al.."/>
 <result pre="norovirus-infected patients. J Clin Microbiol. (2017) 55:3366–73. 10.1128/JCM.00865-1728904188 126.HutsonAMAiraudFLePenduJEstesMKAtmarRL. Norwalk" exact="virus infection" post="associates with secretor status genotyped from sera. J Med"/>
 <result pre="patients. J Clin Microbiol. (2017) 55:3366–73. 10.1128/JCM.00865-1728904188 126.HutsonAMAiraudFLePenduJEstesMKAtmarRL. Norwalk virus" exact="infection" post="associates with secretor status genotyped from sera. J Med"/>
 <result pre="from sera. J Med Virol. (2005) 77:116–20. 10.1002/jmv.2042316032732 127.NewmanKLMoeCLKirbyAEFlandersWDParkosCALeonJS. Human" exact="norovirus infection" post="and the acute serum cytokine response. Clin Exp Immunol."/>
 <result pre="sera. J Med Virol. (2005) 77:116–20. 10.1002/jmv.2042316032732 127.NewmanKLMoeCLKirbyAEFlandersWDParkosCALeonJS. Human norovirus" exact="infection" post="and the acute serum cytokine response. Clin Exp Immunol."/>
 <result pre="Virol. (2005) 77:116–20. 10.1002/jmv.2042316032732 127.NewmanKLMoeCLKirbyAEFlandersWDParkosCALeonJS. Human norovirus infection and the" exact="acute" post="serum cytokine response. Clin Exp Immunol. (2015) 182:195–203. 10.1111/cei.1268126178578"/>
</results>
